Henry Schein (HSIC)
(Delayed Data from NSDQ)
$71.94 USD
-0.96 (-1.32%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $71.96 +0.02 (0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$71.94 USD
-0.96 (-1.32%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $71.96 +0.02 (0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth D Momentum B VGM
Zacks News
Can Invisalign Drive Align Technology's (ALGN) Q4 Earnings?
by Zacks Equity Research
Align Technology (ALGN) poised to gain from strength in the Invisalign space as well as Scanner and Service business in Q4.
Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to gain on continued growth in Diagnostics business in Q4.
Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.
Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings?
by Zacks Equity Research
ResMed (RMD) poised to ride high on continued growth in domestic as well as overseas business in Q2.
Henry Schein (HSIC) Buys ABASE, Expands in Animal Health
by Zacks Equity Research
Henry Schein (HSIC) forges ahead with deals to strengthen the Global Animal Health business.
Patterson Companies' (PDCO) Dental Segment Shows Weakness
by Zacks Equity Research
Changing healthcare environment in the United States, unfavorable price movements and competitive dental products industry are posing challenges for Patterson Companies, Inc. (PDCO).
Henry Schein Buys eVetPractice, Boosts Technology & VAS Arm
by Zacks Equity Research
Henry Schein (HSIC) adopts initiatives to strengthen hold in the high-potential healthcare IT market.
Rising Costs Hurt Henry Schein, End-Market Trends a Tailwind
by Zacks Equity Research
Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.
Implied Volatility Surging for Henry Schein (HSIC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Henry Schein (HSIC) stock based on the movements in the options market lately.
Henry Schein (HSIC) Misses Q3 Earnings, Margins Decline
by Zacks Equity Research
Henry Schein (HSIC) maintains stellar top-line performance in Q3, courtesy of strength in all business segments.
Henry Schein (HSIC) Misses Q3 Earnings, Revenues Beat Estimate
by Zacks Equity Research
Henry Schein (HSIC) gains from strength in all the business segments in Q3.
Can DENTSPLY (XRAY) Deliver a Beat This Earnings Season?
by Zacks Equity Research
In the third quarter, DENTSPLY (XRAY) is expected to witness strong growth in revenues, particularly in the dental consumables and laboratories segment.
4 Medical Device Stocks to Top Q3 Earnings
by Zacks Equity Research
A look at how medical device players are poised for this earnings season.
Key Factors to Influence PerkinElmer's (PKI) Q3 Earnings
by Zacks Equity Research
PerkinElmer's (PKI) divestiture of the Medical Imaging segment in the last quarter is expected to impact earnings this season.
Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?
by Zacks Equity Research
Hologic (HOLX) is expected to deliver solid results in Q4 on the back of the increasing market share and utilization of fully-automated Panther system.
AmerisourceBergen (ABC) Q4 Earnings: Will it Disappoint?
by Zacks Equity Research
The temporary slowdown in the PharMEDium segment is expected to mar AmerisourceBergen's (ABC) bottom line in the fourth quarter
Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?
by Zacks Equity Research
CVS Health (CVS) is expected to post another quarter of solid top-line performance on the back of gains from the Pharmacy Services segment.
Is Becton, Dickinson (BDX) Poised for a Beat in Q4 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) large base of product pipeline, industry-leading technologies and collaborations are growth propellers in Q4.
Ecolab (ECL) to Report Q3 Earnings: Will It Disappoint?
by Zacks Equity Research
Ecolab's (ECL) large base of recurring revenues, industry-leading technologies and excellent field service are propellers. However, the company faces cut-throat competition in the niche space.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?
by Zacks Equity Research
Myriad Genetics (MYGN) is positioned to deliver solid results in Q1 on the back of the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.
What's in Store for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH), a global player in the healthcare services and products space, has been grappling with pricing deflation in the generics segment in the first quarter.
Henry Schein (HSIC) Q3 Earnings to Show Growth in All Lines
by Zacks Equity Research
Henry Schein (HSIC) likely to gain on strength across all business segments in Q3.
Will Higher System Sales Drive Cerner's (CERN) Q3 Earnings?
by Zacks Equity Research
Strong growth in licensed software and subscriptions are expected to be the main factors driving systems revenues for Cerner (CERN) in the third quarter of 2017.
Will Sage-Unit Recall Hurt Stryker's (SYK) Q3 Earnings?
by Zacks Equity Research
In August, Stryker (SYK) announced a voluntary recall of the Oral Care line-up, which was offered by the company's Sage-Products unit.
Mckesson (MCK) to Report Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
McKesson Corporation (MCK) expects a strong second quarter owing to a gradually stabilizing generic and branded market.